PTC Therapeutics, Inc. (PTCT) wird mit einem nachlaufenden KGV von gehandelt 8.4, erwartetes KGV von 77.4. Die nachlaufende Gewinnrendite beträgt 11.92%, erwartete Gewinnrendite 1.29%. PEG 1.26.
Durch diese Seite bewiesene Kriterien:
SharesGrow Gesamtbewertung: 74/100 mit 5/7 Kriterien bestanden.
| Year | P/E (TTM) | PEG-Verhältnis | P/B-Verhältnis | P/S-Verhältnis | Dividendenrendite |
|---|---|---|---|---|---|
| 2016 | -2.6 | 0.15 | 3.11 | 4.49 | - |
| 2017 | -8.3 | 0.16 | 4.17 | 3.36 | - |
| 2018 | -12.5 | -0.35 | 4.56 | 6.04 | - |
| 2019 | -11.2 | -0.20 | 4.76 | 9.21 | - |
| 2020 | -9.2 | -0.17 | 8.36 | 10.58 | - |
| 2021 | -5.4 | -0.45 | 1,951.79 | 5.21 | - |
| 2022 | -4.9 | -1.01 | -7.89 | 3.92 | - |
| 2023 | -3.3 | -0.44 | -2.52 | 2.20 | - |
| 2024 | -9.5 | 0.22 | -3.16 | 4.30 | - |
| 2025 | 8.9 | -0.03 | -29.43 | 3.49 | - |
| Year | EPS (verwässert) | Umsatz | Nettogewinn | Nettomarge |
|---|---|---|---|---|
| 2016 | $-4.17 | $82.71M | $-142.11M | -171.8% |
| 2017 | $-2.02 | $194.39M | $-79M | -40.6% |
| 2018 | $-2.75 | $264.73M | $-128.08M | -48.4% |
| 2019 | $-4.27 | $306.98M | $-251.58M | -82% |
| 2020 | $-6.64 | $380.77M | $-438.16M | -115.1% |
| 2021 | $-7.43 | $538.59M | $-523.9M | -97.3% |
| 2022 | $-7.79 | $698.8M | $-559.02M | -80% |
| 2023 | $-8.37 | $937.82M | $-626.6M | -66.8% |
| 2024 | $-4.73 | $806.78M | $-363.3M | -45% |
| 2025 | $7.78 | $1.73B | $682.64M | 39.4% |
| Year | EPS (Durchschn.) | EPS-Spanne | Umsatz (Durchschn.) | Umsatzspanne | Analysten |
|---|---|---|---|---|---|
| 2026 | $-0.97 | $-3.62 – $1.92 | $931.11M | $764.29M – $1.01B | 7 |
| 2027 | $0.93 | $0.30 – $1.71 | $1.1B | $926.59M – $1.36B | 6 |
| 2028 | $0.57 | $-3.89 – $3.39 | $1.27B | $1.27B – $1.27B | 6 |
| 2029 | $2.98 | $2.21 – $3.68 | $1.43B | $1.15B – $1.69B | 4 |
| 2030 | $3.99 | $2.95 – $4.92 | $1.56B | $1.25B – $1.84B | 2 |
